Dennis Ding
Stock Analyst at Jefferies
(1.84)
# 3,314
Out of 5,090 analysts
15
Total ratings
40%
Success rate
5.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $18 → $20 | $21.13 | -5.35% | 2 | Sep 18, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Hold | $15 → $26 | $38.74 | -32.89% | 2 | Sep 3, 2025 | |
| INDV Indivior | Assumes: Buy | $20 | $35.06 | -42.95% | 1 | Jul 22, 2025 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $47.06 | +16.87% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $1.49 | +436.91% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $35.36 | -1.02% | 1 | Sep 20, 2024 | |
| FOLD Amicus Therapeutics | Initiates: Buy | $18 | $9.98 | +80.45% | 1 | Sep 6, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $4.41 | +58.73% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $4.74 | +26.58% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $500 → $25 | $4.33 | +478.03% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $35 → $22 | $86.29 | -74.50% | 1 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $35.19 | -31.80% | 1 | Dec 19, 2022 |
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $18 → $20
Current: $21.13
Upside: -5.35%
Mineralys Therapeutics
Sep 3, 2025
Maintains: Hold
Price Target: $15 → $26
Current: $38.74
Upside: -32.89%
Indivior
Jul 22, 2025
Assumes: Buy
Price Target: $20
Current: $35.06
Upside: -42.95%
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $47.06
Upside: +16.87%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $1.49
Upside: +436.91%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $35.36
Upside: -1.02%
Amicus Therapeutics
Sep 6, 2024
Initiates: Buy
Price Target: $18
Current: $9.98
Upside: +80.45%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $4.41
Upside: +58.73%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $4.74
Upside: +26.58%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $500 → $25
Current: $4.33
Upside: +478.03%
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $86.29
Upside: -74.50%
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $35.19
Upside: -31.80%